Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections
Chagas disease is caused by infection with the protozoan pathogen, Trypanosoma cruzi. The only approved therapeutics for treating Chagas disease are two nitroheterocydic compounds (benznidazole and nifurtimox) that are suboptimal due to poor curative activity for chronic Chagas disease and high rates of adverse drug reactions. Sterol 14-demethylase inhibitors include azole antifungal drugs such as ketoconazole, fluconazole, itraconazole, and others. The first reports of potent activity of azole antifungal drugs against Trypanosoma cruzi came out about 25 years ago. Since then, a sizeable literature has accumulated on this topic. Newer triazole compounds such as posaconazole and D0870 have been shown to be effective at curing mice with chronic Trypanosoma cruzi infection. Small clinical studies with ketoconazole or itraconazole in humans with chronic Chagas disease have not demonstrated significant curative activity. However, there is good reason for optimism that newer compounds with greater potency and improved pharmacokinetic properties might be more efficacious. Data have been published demonstrating synergistic activity of azole drugs with various other compounds, indicating that combination chemotherapy may be an effective strategy as this field moves ahead. In light of the near absence of adequate therapeutics for curing patients with chronic Chagas disease, additional effort to develop better drugs needs to be a priority.
KeywordsAntimicrob Agent Trypanosoma Cruzi Sterol Biosynthesis Azole Drug Sterol Biosynthesis Inhibitor
Unable to display preview. Download preview PDF.
- 2.World Health Organization. Control of Chagas’ disease. WHO Tech Rep Ser 1991; 811:1–93.Google Scholar
- 3.Eisen H, Petry K, Van Voorhis WC. The origin of autoimmune pathology associated with Trypanosoma cruzi infection. In: Van Der Ploeg LHT, Cantor CR, Voegel HJ, eds. Immune Recognition and Evasion: Molecular Aspects of Host-Parasite Interaction. London: Academic Press Inc., 1990:91–103.Google Scholar
- 6.Sosa ES, Segura EL, Ruiz AM et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 1998; 59:526–29.Google Scholar
- 7.Pan American Health Organization/World Health Organization. Etiological treatment for Chagas disease. Rev Pat Trop 1998; 28:247–79.Google Scholar
- 9.Lamb DC, Kelly DE, Waterman MR et al. Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 1999; 15:755–63.PubMedCrossRefGoogle Scholar
- 11.Rozman D, Stromstedt M, Waterman MR. The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: Structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch Biochem Biophys. 1996; 333:466–74.PubMedCrossRefGoogle Scholar
- 54.Molina J, Martins-Filho O, Brener Z et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000; 44:150–55.PubMedGoogle Scholar